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the  dawn  of  the  antibiotic  era,  pioneered  by
hrlich, Domagk,  Fleming  and  Waksman  brought,
 new  freedom  from  the  fear  of  premature  loss
f life  due  to  infectious  disease.  Prostitutes  were
leansed,  wounded  soldiers  came  home,  TB  sana-
oriums  were  emptied  and  modern  medicine  was
rmly established.  However,  only  a  century  after
he development  of  salvarsan,  the  ﬁrst  useful  drug
gainst syphilis,  we  ﬁnd  ourselves  in  a  world  that
s sadly  complacent.  Lack  of  sufﬁcient  proﬁts  from
ntibiotics  that  cure  has  caused  many  pharmaceu-
ical companies  to  abandon  antibiotic  discovery
rogrammes [1]. They  prefer  to  focus  on  the  large
roﬁts  made  from  drugs  that  relieve  symptoms  but
o not  cure.  At  the  other  end  of  the  spectrum,
arge proﬁts  delivered  from  the  growth  promoting
ffects of  feeding  antibiotics  to  healthy  animals
ave produced  a  powerful  and  constant  selective
ressure for  the  emergence  of  new  bacterial  resis-
ance mechanisms.  In  addition,  many  countries
ave never  introduced  prescriptive  controls  on  the
se of  antibiotics  and  some  of  these  have  huge
opulations with  heavy  antibiotic  use.  This  has  left
s in  a  situation  where  common  infections  due
o Klebsiella  pneumoniae  and  Escherichia  coli  are
ecoming  difﬁcult  and  in  some  cases  impossible  to
reat. Global  travel  and  medical  tourism  have  also
nabled these  resistant  bacteria  to  easily  dissemi-
ate  world-wide  [2].
At the  heart  of  the  emergence  of  antibiotic  resis-
ance  is  an  amazing  paradox.  A  great  deﬁnition  of
 paradox  is  ‘‘A  small  truth  sitting  on  a  large  truth
nd running  in  the  opposite  direction’’  and  many
aradoxes  take  this  form.  Thus  paradox  is  a  place
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ttp://dx.doi.org/10.1016/j.jiph.2013.12.001here  two  opposite  and  contradictory  truths  are
oth true  at  the  same  time.  Since  the  small  truth
its on  top  of  the  large  truth,  human  nature  is  such
hat we  quickly  recognise  the  small  truth  and  ignore
he large  truth.  An  example  of  a  paradox  taking
his form  is  ‘‘the  lottery’’.  Here  the  small  truth
s ‘‘the  lottery  makes  people  rich’’.  This  is  true
nd well-advertised  but  statistically  irrelevant.  The
ubstantial truth  found  just  below  the  veneer  of
he small  truth  is  ‘‘the  lottery  makes  most  people
oorer’’  (Fig.  1).  For  the  antibiotic  resistance  para-
ox, the  small  truth  is  that  antibiotic  resistance  is
n example  of the  survival  of  the  ﬁttest.  However,
he large  truth  is  described  in  a recent  review  by
wo experts  in  the  study  of  antibiotic  resistance  and
tness costs.  Here  we  are  told  that  ‘‘most  antibiotic
esistance  mechanisms  are  associated  with  a  ﬁt-
ess cost  that  typically  expresses  itself  as  a reduced
rowth  rate’’  [3]. This  means  that  antibiotic  resis-
ance is  an  amazing  example  of  survival  of  the  less
t and  it is  these  inferior,  less  ﬁt  bacteria  that  are
ur problem  today  (Fig.  1). This  is  because  we  live  in
 world  that  we  have  polluted  with  antibiotics  cre-
ting a  perfect  environment  for  less  ﬁt  organisms
o survive.  Be  it  in  the  hospital,  the  community  or
n the  farm  our  overuse,  misuse  and  abuse  of  these
ife-saving  drugs  is  rapidly  causing  a regression  to
he pre-antibiotic  era.
The rapid  emergence  of  antibiotic  resistance
n Gram-negative  bacteria  is  highlighted  by
he Extended  Spectrum  -Lactamases  (ESBLs).
hese typically  give  resistance  to  the  widely
sed third  generation  cephalosporin  antibiotics
4]. The  most  prevalent  ESBLs  are  the  CTX-M
roup, ﬁrst  described  in  1990  from  Munich,
ermany [5]. Since  its  initial  emergence  there
ave been  148  variants  of  this  enzyme  recorded
http://www.lahey.org/Studies/other.asp#table1),
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Figure  1  Opposite  and  contradictory  truths  associated  with  paradox.  Paradox  often  takes  the  form  of  a  small  truth
found  on  top  of  a  large  truth.  Human  nature  is  such  that  the  small  truth  is  quickly  observed  whilst  the  greater  truth
goes  un-noticed.  (A)  An  example  of  a  common  paradox  of  the  lottery  where  the  small  truth  is  statistically  irrelevant.
ruth
i

t
m
p
r
K
i
A
w
a
a
(
d
f
i
i
p
u
t
s
c
s
a
E
i
c
m
U
i
s
b
a
[
o
s
t
c(B)  Antibiotic  resistance  is  a  paradox  where  the  greater  t
the  less  ﬁt.
the  most  prevalent  and  pervasive  being  CTX-M-15
[6,7].  The  initial  description  of  CTX-M-15  was
from New  Delhi  in  1999  [7]  and  third  generation
cephalosporin  resistance  in  E.  coli  and  K.  pneumo-
niae is  mostly  caused  by  this  resistance  mechanism
worldwide [6]. CTX-M-15  was  acquired  by  enteric
bacteria  from  a  harmless  environmental  water
loving bacterium  called  Kluvera  [8]. The  gene  was
captured  by  a  transposon  called  ISEcP1  that  moved
it off  the  Kluvera  chromosome  onto  a  plasmid  and
then into  a  wide  range  of  different  bacteria  [6,8].
The prevalence  of  this  mechanism  in  E.  coli  ranges
from  less  than  1%  in  blood  infections  in  Northern
Europe to  30—60%  in  the  Asia-paciﬁc  region  (not
including India)  to  80%  in  India  [9].  Typically,  the
rates of  resistance  due  to  CTX-M-15  are  lower  in  the
community  than  those  found  in  hospitals.  However,
in India  there  is  little  difference  between  the  rates
of resistance  found  in  the  hospital  to  those  found  in
the community  [9]  and  recent  information  records
carriage  levels  in  S.  Asia  as  high  as  89%.  These
mechanisms can  easily  be  transferred  between
countries by  gut  colonisation  and  travel  [10]. For
example,  the  chances  of  acquiring  an  enteric
organism producing  CTX-M-15  is  88%  with  a  two
week  visit  to  India  [10]. This  is  further  illustrated
by a  study  in  the  UK  revealing  that  carriage  of
this mechanism  in  people  with  Asian  surnames
is three  times  as  high  as  people  with  European
surnames [11]. The  fact  that  there  are  no  controls
on antibiotic  sales  in  India  is  likely  a  major  factor
why India  has  the  largest  known  resistance  problem
[9].  Thus,  in  a  little  over  a  decade  CTX-M-15  has
emerged and  spread  to  most  parts  of  the  world.
The high  prevalence  of  CTX-M-15  infections  has
resulted  in  increasing  morbidity  and  mortality  due
to delayed  appropriate  therapy  [12,13].  It  has  also
driven a  dependence  on  carbapenems  which  are
our last  safe  and  useful  antibiotics,  kept  in  reserve
for life  threatening  infections  [14,15].
Carbapenem  resistance  in  enteric  organisms
became a  signiﬁcant  problem  over  the  last  decade
[
t
a
i is  that  antibiotic  resistance  is  an  example  of  survival  of
nitially  in  Greece  and  mostly  due  to  the  metallo-
-lactamase gene  VIM-1  [16]. Resistance  rates  in
he ICU  rose  to  80%  and  quickly  spread  through
ost Greek  hospitals.  Greece  now  has  the  greatest
roblem of  bacterial  resistance  in  Europe.  More
ecently, VIM-1  appears  to  be  being  replaced  by
PC [17], a carbapenemase  prevalent  in  Klebsiella
solates that  originated  in  the  United  States  of
merica [18]. The  USA  is  another  country  that  is
ell known  for  misusing  antibiotics  with  80%  of
ll antibiotics  being  used  for  agricultural  use  and
 large  proportion  of  this  for  growth  promotion
http://www.pewhealth.org/reports-analysis/
ata-visualizations/record-high-antibiotic-sales-
or-meat-and-poultry-production-85899449165).  It
s not  perhaps  surprising  then  that  KPC  emerged
n a  US  State  that  is  well  known  for  intensive
ig farming  with  its  concomitant  heavy  antibiotic
se. Since  its  emergence  in  North  Carolina  in
he late  1990s,  KPC  spread  along  the  eastern
eaboard of  the  US.  This  caused  long  term  and
ontinuing problems  in  New  York  before  steadily
preading across  the  continent  towards  the  paciﬁc
nd also  disseminating  to  Israel,  South  America,
urope and  South  East  Asia  [19]. Typically  KPC
s predominantly  found  in  K.  pneumoniae  and
arbapenem resistance  in  K.  pneumoniae  is  the
ost signiﬁcant  challenge  to  health  care  in  the
S with  resistance  being  recorded  in  some  ICUs
n the  New  York  region  as  high  as  38%  [20].  The
ituation  has  been  exasperated  by  KPC  often
eing found  in  K.  pneumoniae  ST258,  a strain  that
ppears to  be  associated  with  signiﬁcant  mortality
20]. KPC  has  also  been  found  in  other  enteric
rganisms and  also  in  non-fermentative  organisms
uch  as  Pseudomonas  aeruginosa. In  addition
o VIM  and  KPC  another  increasingly  prevalent
arbapenemase  in  enteric  organisms  is OXA-48
21]. This  carbapenemase  emerged  in  Turkey  at
he turn  of  the  century  and  associated  mostly  with
 single  plasmid.  Since  then  a few  clonal  outbreaks
n Turkey  have  spread  into  an  endemic  problem
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ahallenge  to  patient  safety  
ithin  Turkey  and  subsequently  to  North  Africa,
urope and  the  Middle-East  [22,23].
Perhaps  the  most  serious  challenge  to  our
urrent antibiotic  armamentarium  is the  emer-
ence of  the  carbapenemase  NDM-1  (the  New
elhi Metallo--lactamase).  The  origins  and  rapid
issemination  of  NDM-1  is following  that  of  CTX-
-15.  The  ﬁrst  descriptions  of  both  CTX-M-15  and
DM-1 were  from  isolates  originating  in  New  Delhi
ospitals  [7,24,25].  Retrospective  studies  have
ince recorded  the  ﬁrst  clinical  isolates  carrying
he NDM-1  gene  (blaNDM-1) dating  from  2006  in
ew Delhi,  yet  already  similar  isolates  have  been
ound in  over  50  countries  and  on  all  continents.
n addition  blaNDM-1 is  found  in  normal  gut  carriage
rganisms such  as  E.  coli.  A  study  of  two  hospitals  in
awalpindi,  Pakistan  found  gut  carriage  of  blaNDM-1
t  14%  in  the  community  and  27%  in  the  hospital
26].  More  recent  studies  in  Pakistan  record  gut  car-
iage as  high  as  36%  in  Karachi  and  40%  in  Islamabad
http://www.escmid.org/escmid  library/online
ecture  library/?search=1&current  page=1&search
erm=Ammara+Mushtaq) and  a  countrywide  study
n China  found  examples  of  gut  carriage  of  NDM-1
n all  52  hospitals  tested  [27].  Therefore  both
TX-M-15 and  NDM-1  resistance  mechanisms  are
arried to  high  levels  especially  in  S.  Asia.  This
nables these  resistance  mechanisms  to  easily
ross international  borders  unseen  as  commensal
ut carriage  organisms.
NDM-1  has  been  described  from  numerous
nteric and  non-fermentative  organisms  but  prin-
ipally from  E.  coli  and  K.  pneumoniae  [2,28].
he emergence  of  carbapenem  resistance  in
. coli  is of  major  concern  since  E.  coli  is our
rincipal bacterial  pathogen  accounting  for  ∼80%
f UTI  infections  and  is  the  commonest  cause
f bacteraemia  across  most  of  Europe  [14]. The
resence  of  E.  coli  and  other  enteric  organisms  in
he gut  carrying  NDM-1  presents  the  real  possibility
f patients  infecting  themselves  with  their  own
esistant  ﬂora  leading  to  treatment  failures  and
ncreasing  risks  and  costs  of  hospital  care.  This
ill likely  impinge  on  the  ability  of  hospitals  to
arry out  normal  surgical  procedures  in  the  future.
DM-1  was  initially  discovered  because  of  its  close
ssociation  with  medical  tourism  to  S.  Asia  and
specially  India  and  these  initial  observations  have
een conﬁrmed  repeatedly  in  the  literature  [29].
hus S.  Asia  is  acting  as  a  massive  reservoir  of
esistant  bacteria  that  is easily  spread  to  the  rest
f the  world  through  travel.  The  situation  in  India
as recently  been  highlighted  at  ECCMID  2013  with
 snapshot  of  resistance  levels  in  a  Chennai  hospital
ecording  NDM-1  in  10%  of  E.  coli  infections,  and
0%, 40%  and  80%  of  Klebsiella, Pseudomonas
c
a
r
m3
nd  Acinetobacter  infections  respectively
http://www.escmid.org/escmid  library/online
ecture  library/?search=1&current  page=1&search
erm=abdul+Ghafur).
Genetic  studies  on  blaNDM-1 have  shown  that
his gene  is  particularly  mobile  being  found  in
umerous  strains  and  species  of  bacteria  as  well
s on  many  different  plasmids  of  diverse  sizes  [2].
n addition,  it  is also  often  acquired  along  with
everal other  resistance  mechanisms  such  as  16S
ibosomal  methylases  that  confer  resistance  to  all
minoglycoside  antibiotics.  As  such  NDM-1  positive
trains  are  usually  resistant  to  all  antibiotics  except
olistin  and  tigycycline  and  occasionally  are  pan
esistant  [30].  Analysis  of  the  genetic  locus  around
laNDM-1 has  revealed  that  it  is often  acquired  along
ith several  other  genes  of  high  GC%  including
enes encoding  the  molecular  chaperone  GroEL/ES
Fig.  2) [31,32]. Interestingly,  overexpression  of
his chaperone  has  a ﬁtness  beneﬁt  and  causes
ncreased growth  rates  of  mutants  [33].  Thus  the
cquisition  of  groEL/ES  genes  along  with  blaNDM-1
ay  enable  this  resistance  mechanism  to  get  over
he previously  mentioned  classical  ﬁtness  defects
hat are  associated  with  resistant  bacteria.  Obser-
ations  of  a large  GC%  change  of  the  DNA  at  the
eginning of  the  blaNDM-1 gene  led  on  to  the  real-
sation that  blaNDM-1 is  a  chimeric  gene  that  has
robably been  made  in  the  last  15  years  [32]. The
himeric  gene  was  produced  by  the  fusion  of  an
minoglycoside  modifying  gene  aphA6  and  a  pre-
ious -lactamase  gene.  It  is  likely  that  the  genetic
usion is  also  involved  in  the  success  of  this  gene.
his may  be  because  of  several  factors  including  a
ew promoter  that  functions  in  a  wide  range  of  bac-
erial species  as  well  as  changes  to  the  structural
rotein itself  and  also  perhaps  post-translational
odiﬁcation  changes  [32].
In summary,  we  are  seeing  the  beginning  of
he end  of  the  antibiotic  age  with  the  emergence
f untreatable  infections  in  several  different  geo-
raphic regions.  This  is due  to  a combination  of  the
isuse and  abuse  of  current  antibiotics  together
ith  a  lack  of  interest  in  developing  new  antibi-
tics.  The  greatest  problem  is  found  in  S.  Asia  where
 number  of  factors  have  come  together  creat-
ng very  high  resistance  rates.  These  include:  high
isease incidence  because  of  poor  sanitation  and
olluted  drinking  water;  poor  vaccination  uptake;
imited  controls  on  the  use  of  antibiotics  and  ease  of
issemination  of  resistance  via  contaminated  food
nd water.  Thus  there  is  a  desperate  need  for  tight
ontrols  of the  use  of  antibiotics  in  both  human  and
nimal medicine,  a ban  on  growth  promotion  and
enewed  incentives  for  antibiotic  discovery.  Such
easures  will  reduce  the  emergence  and  spread  of
4  Editorial
Figure  2  GC%  change  in  the  vicinity  of  the  NDM-1  gene  (blaNDM-1).  The  GC%  is  measured  by  a  sliding  window  of  30
nucleotides  and  recorded  as  a  graph  below  the  blaNDM-1 locus.  The  blaNDM-1 locus  is  drawn  using  coloured  open  boxes  to
depict  genes.  The  large  GC%  change  at  the  beginning  of  the  bla gene  from  ∼40%  GC  to  ∼60%  GC  is  shown  below
d  lab
ved  
[
[
[
[
[
[
[
[the  blaNDM-1 gene  which  is  drawn  as  a  yellow  open  box  an
often  acquired  at  the  same  time  as  blaNDM-1 and  are  invol
resistance  mechanisms  due  to  the  removal  of  selec-
tive pressure  for  less  ﬁt  bacteria  whilst  creating
a selective  advantage  for  wild  type  non-resistant
bacteria.
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